154 related articles for article (PubMed ID: 20527893)
1. Selective hexapeptide agonists and antagonists for human complement C3a receptor.
Scully CC; Blakeney JS; Singh R; Hoang HN; Abbenante G; Reid RC; Fairlie DP
J Med Chem; 2010 Jul; 53(13):4938-48. PubMed ID: 20527893
[TBL] [Abstract][Full Text] [Related]
2. The C3a receptor antagonist SB 290157 has agonist activity.
Mathieu MC; Sawyer N; Greig GM; Hamel M; Kargman S; Ducharme Y; Lau CK; Friesen RW; O'Neill GP; Gervais FG; Therien AG
Immunol Lett; 2005 Sep; 100(2):139-45. PubMed ID: 16154494
[TBL] [Abstract][Full Text] [Related]
3. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
[TBL] [Abstract][Full Text] [Related]
4. Modulation of C3a activity: internalization of the human C3a receptor and its inhibition by C5a.
Settmacher B; Bock D; Saad H; Gärtner S; Rheinheimer C; Köhl J; Bautsch W; Klos A
J Immunol; 1999 Jun; 162(12):7409-16. PubMed ID: 10358194
[TBL] [Abstract][Full Text] [Related]
5. Potent heterocyclic ligands for human complement c3a receptor.
Reid RC; Yau MK; Singh R; Hamidon JK; Lim J; Stoermer MJ; Fairlie DP
J Med Chem; 2014 Oct; 57(20):8459-70. PubMed ID: 25259874
[TBL] [Abstract][Full Text] [Related]
6. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
[TBL] [Abstract][Full Text] [Related]
7. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models.
Ames RS; Lee D; Foley JJ; Jurewicz AJ; Tornetta MA; Bautsch W; Settmacher B; Klos A; Erhard KF; Cousins RD; Sulpizio AC; Hieble JP; McCafferty G; Ward KW; Adams JL; Bondinell WE; Underwood DC; Osborn RR; Badger AM; Sarau HM
J Immunol; 2001 May; 166(10):6341-8. PubMed ID: 11342658
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of the C3a and C5a receptors (CD88) by IFN-gamma and PMA in U937 cells and related myeloblastic cell lines.
Burg M; Martin U; Bock D; Rheinheimer C; Köhl J; Bautsch W; Klos A
J Immunol; 1996 Dec; 157(12):5574-81. PubMed ID: 8955209
[TBL] [Abstract][Full Text] [Related]
9. Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a.
Petering H; Köhl J; Weyergraf A; Dulkys Y; Kimmig D; Smolarski R; Kapp A; Elsner J
J Immunol; 2000 Apr; 164(7):3783-9. PubMed ID: 10725738
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
[TBL] [Abstract][Full Text] [Related]
11. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells.
Crass T; Raffetseder U; Martin U; Grove M; Klos A; Köhl J; Bautsch W
Eur J Immunol; 1996 Aug; 26(8):1944-50. PubMed ID: 8765043
[TBL] [Abstract][Full Text] [Related]
12. De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation.
Bellows-Peterson ML; Fung HK; Floudas CA; Kieslich CA; Zhang L; Morikis D; Wareham KJ; Monk PN; Hawksworth OA; Woodruff TM
J Med Chem; 2012 May; 55(9):4159-68. PubMed ID: 22500977
[TBL] [Abstract][Full Text] [Related]
13. Cloning and characterization of rat C3a receptor: differential expression of rat C3a and C5a receptors by LPS stimulation.
Fukuoka Y; Ember JA; Hugli TE
Biochem Biophys Res Commun; 1998 Jan; 242(3):663-8. PubMed ID: 9464274
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning of two isoforms of the guinea pig C3a anaphylatoxin receptor: alternative splicing in the large extracellular loop.
Fukuoka Y; Ember JA; Hugli TE
J Immunol; 1998 Sep; 161(6):2977-84. PubMed ID: 9743361
[TBL] [Abstract][Full Text] [Related]
15. C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent.
Ducruet AF; Hassid BG; Mack WJ; Sosunov SA; Otten ML; Fusco DJ; Hickman ZL; Kim GH; Komotar RJ; Mocco J; Connolly ES
J Cereb Blood Flow Metab; 2008 May; 28(5):1048-58. PubMed ID: 18197178
[TBL] [Abstract][Full Text] [Related]
16. Expression of high- and low-affinity receptors for C3a on the human mast cell line, HMC-1.
Legler DF; Loetscher M; Jones SA; Dahinden CA; Arock M; Moser B
Eur J Immunol; 1996 Apr; 26(4):753-8. PubMed ID: 8625964
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells.
Takabayashi T; Shimizu S; Clark BD; Beinborn M; Burke JF; Gelfand JA
Surgery; 2004 May; 135(5):544-54. PubMed ID: 15118592
[TBL] [Abstract][Full Text] [Related]
18. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists.
Li XX; Clark RJ; Woodruff TM
Int Immunopharmacol; 2021 Nov; 100():108074. PubMed ID: 34454293
[TBL] [Abstract][Full Text] [Related]
19. Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity.
Rowley JA; Reid RC; Poon EKY; Wu KC; Lim J; Lohman RJ; Hamidon JK; Yau MK; Halili MA; Durek T; Iyer A; Fairlie DP
J Med Chem; 2020 Jan; 63(2):529-541. PubMed ID: 31910011
[TBL] [Abstract][Full Text] [Related]
20. Identification of ligand effector binding sites in transmembrane regions of the human G protein-coupled C3a receptor.
Sun J; Ember JA; Chao TH; Fukuoka Y; Ye RD; Hugli TE
Protein Sci; 1999 Nov; 8(11):2304-11. PubMed ID: 10595533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
